[PDF][PDF] Dimerization contributes to oncogenic activation of MLL chimeras in acute leukemias

CW So, M Lin, PM Ayton, EH Chen, ML Cleary - Cancer cell, 2003 - cell.com
CW So, M Lin, PM Ayton, EH Chen, ML Cleary
Cancer cell, 2003cell.com
MLL is a histone methyltransferase that can be converted into an oncoprotein by acquisition
of transcriptional effector domains following heterologous protein fusions with a variety of
nuclear transcription factors, cofactors, or chromatin remodeling proteins in acute leukemias.
Here we demonstrate an alternative mechanism for activation of MLL following fusions with
proteins (AF1p/Eps15 and GAS7) that normally reside in the cytoplasm. The coiled-coil
oligomerization domains of these proteins are necessary and sufficient for leukemogenic …
Abstract
MLL is a histone methyltransferase that can be converted into an oncoprotein by acquisition of transcriptional effector domains following heterologous protein fusions with a variety of nuclear transcription factors, cofactors, or chromatin remodeling proteins in acute leukemias. Here we demonstrate an alternative mechanism for activation of MLL following fusions with proteins (AF1p/Eps15 and GAS7) that normally reside in the cytoplasm. The coiled-coil oligomerization domains of these proteins are necessary and sufficient for leukemogenic transformation induced by the respective MLL fusion proteins. Furthermore, homodimerization of MLL by synthetic dimerization modules mimics bona fide MLL fusion proteins resulting in Hox gene activation and enhanced self-renewal of hematopoietic progenitors. Our studies support an oligomerization-dependent mechanism for oncogenic conversion of MLL, presumably in part by recruitment of accessory factors through the dimerized MLL moiety of the chimeric protein.
cell.com